Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “formulation”

865 pharma patents match "formulation" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 865
Index total 30,257
Page 5 / 37

Quick answer

This filtered view shows 865 pharmaceutical patents matching "formulation" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

865 results for “formulation” · 30,257 patents in full index Clear search

  1. US 12053444

    Therapeutic compounds, formulations, and uses thereof

    Tvardi Therapeutics, Inc. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  2. US 12054758

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  3. US 12048691

    High dosage tebipenem pivoxil tablet formulation

    SPERO THERAPEUTICS, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  4. US 12049652

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  5. US 12042558

    Method and formulation for improving roflumilast skin penetration lag time

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  6. US 12042479

    Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders

    INMED PHARMACEUTICALS INC. · Granted Jul 23, 2024 · Expires Jul 18, 2044

    granted
  7. US 12036280

    High concentration protein formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  8. US 12037618

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jul 16, 2024 · Expires Jul 11, 2044

    granted
  9. US 12017989

    Controlled release pharmaceutical formulations

    United Therapeutics Corporation · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  10. US 12016929

    Lipid formulations for delivery of therapeutic agents

    ARBUTUS BIOPHARMA CORPORATION · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  11. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  12. US 12018298

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  13. US 12011437

    Roflumilast formulations with an improved pharmacokinetic profile

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  14. US 12005052

    Topical roflumilast formulation having improved delivery and plasma half-life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  15. US 12005060

    Ophthalmic formulations of methotrexate

    Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  16. US 12005051

    Topical roflumilast formulation having improved delivery and plasma half life

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  17. US 12005061

    Ophthalmic formulations of methotrexate

    Aldeyra Therapeutics, Inc. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  18. US 12005139

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  19. US 11998604

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  20. US 11998639

    Formulations of (R)-2-amino-3-phenylpropyl carbamate

    AXSOME MALTA LTD. · Granted Jun 4, 2024 · Expires May 30, 2044

    granted
  21. US 11992530

    Therapeutic uses for sodium thiosulfate and formulations

    Fennec Pharn ceuticals Inc. · Granted May 28, 2024 · Expires May 23, 2044

    granted
  22. US 11969501

    Auris formulations for treating otic diseases and conditions

    The Regents of the University of California · Granted Apr 30, 2024 · Expires Apr 25, 2044

    granted
  23. US 11964018

    Therapeutic uses for sodium thiosulfate formulations

    Fennec Pharmaceuticals, Inc. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted
  24. US 11964047

    Ophthalmic formulations and related methods

    ETERNATEAR, INC. · Granted Apr 23, 2024 · Expires Apr 18, 2044

    granted